Cost-Effectiveness of Buprenorphine and Naltrexone Treatments for Heroin Dependence in Malaysia

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Ruger, Jennifer Prah ^a   Chawarski, Marek ^a   Mazlan, Mahmud ^b   Ng, Nora ^a   Schottenfeld, Richard ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Substance Abuse Center   (Malaysia)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; NALTREXONE; OPIATE; PLACEBO;

AIDS RISK INVENTORY; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG DETOXIFICATION; DRUG EFFICACY; DRUG USE; HEALTH CARE POLICY; HEALTH CARE UTILIZATION; HEROIN DEPENDENCE; HIGH RISK BEHAVIOR; HUMAN; INTRAVENOUS DRUG ABUSE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALAYSIA; OUTCOME ASSESSMENT; PATIENT COUNSELING; PRODUCTIVITY; PUBLIC HEALTH; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SCORING SYSTEM; SEXUAL BEHAVIOR; WITHDRAWAL SYNDROME;

ACQUIRED IMMUNODEFICIENCY SYNDROME; BUPRENORPHINE; COST-BENEFIT ANALYSIS; HEROIN DEPENDENCE; HUMANS; MALAYSIA; NALTREXONE; RISK FACTORS; RISK-TAKING; TREATMENT OUTCOME;

EID: 84870754717     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0050673     Document Type: Article

References (31)

1. United Nations Office on Drugs and Crime (2010) World drug report, 2010. E.10.XI.13. Vienna: UNODC. Available: http://www.unodc.org/documents/wdr/WDR_2010/World_Drug_Report_2010_lo-res.pdf. Accessed 18 October 2010.
2. Mazlan M, Schottenfeld RS, Chawarski MC, (2006) New challenges and opportunities in managing substance abuse in Malaysia. Drug Alcohol Rev 25: 473-478.
3. Ministry of Health Malaysia/World Health Organization. Consensus report on HIV and AIDS: epidemiology in 2004: Malaysia. Available: http://www.wpro.who.int/NR/rdonlyres/47E92EB0-3F10-45D9-BF7A-AEDCBF4A5E22/0/Consensus_Report_MAA_2004.pdf. Accessed 18 October 2010.
4. Schottenfeld RS, Chawarski MC, Mazlan M, (2008) Maintenance treatment with buprenorphine and naltrexone for heroin dependence in Malaysia: a randomized, double-blind, placebo-controlled trial. Lancet 371(9631): 2190-2200.
5. Chawarski MC, Mazlan M, Schottenfeld RS, (2008) Behavioral drug and HIV risk reduction counseling (BDRC) with abstinence-contingent take-home buprenorphine: a pilot randomized clinical trial. Drug Alcohol Depend 94: 281-284.
6. Barnett PG, Zaric GS, Brandeau M, (2001) The cost-effectiveness of buprenorphine maintenance therapy for opiate addiction in the United States. Addiction 96(9): 1267-1278.
7. Harris AH, Gospodarevskaya E, Ritter AJ, (2005) A randomized trial of the cost effectiveness of buprenorphine as an alternative to methadone maintenance treatment for heroin dependence in a primary care setting. Pharmacoecon 23(1): 77-91.
8. Shanahan MD, Doran CM, Digiusto E, Bell J, Lintzeris N, et al. (2006) A cost-effectiveness analysis of heroin detoxification methods in the Australian National Evaluation of Pharmacotherapies for Opioid Dependence (NEPOD). Addict Behav 31(3): 371-387.
9. Connock M, Juarez-Garcia A, Jowett S, Frew E, Liu Z, et al. (2007) Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation. Health Technol Assess 11(9): 1-171.
10. Chawarski MC, Schottenfeld RS, Pakes J, Avants K (1997) AIDS Risk Inventory (ARI): a structured interview for assessing risk of HIV infection in a population of drug abusers. In: Harris LS, editor. Problems of Drug Dependence, 1996: Proceedings of the 58th Annual Scientific Meeting of the College on Problems of Drug Dependence, NIDA Research Monograph number 174. Rockville: National Institute on Drug Abuse. p.188.
11. McLellan T, Luborsky L, O'Brien CP, Woody GE, (1980) An improved diagnostic instrument for substance abuse patients: the Addiction Severity Index. J Nerv Ment Dis 168: 26-33.
12. Ruger JP, Chawarski M, Mazlan M, Luekens C, Ng N, et al. (2012) Costs of addressing heroin addiction in Malaysia and 32 comparable countries worldwide. Health Serv Res 47: 865-887.
13. Gold MR, Siegel JE, Russell LB, Weinstein MC, editors (1996) Cost-effectiveness in health and medicine. New York: Oxford University Press.
14. Pattanaphesaj J, Teerawattananon Y, (2010) Reviewing the evidence on effectiveness and cost-effectiveness of HIV prevention strategies in Thailand. BMC Public Health 10: 401.
15. Xing Y, Sun J, Cao W, Lee L, Guo H, et al. (2012) Economic evaluation of methadone maintenance treatment in HIV/AIDS control among injecting drug users in Dehong, China. AIDS Care 24: 756-762.
16. Olmstead TA, Petry NM, (2009) The cost-effectiveness of prize-based and voucher-based contingency management in a population of cocaine- or opioid-dependent outpatients. Drug Alcohol Depend 102(1-3): 108-115.
17. Minozzi S, Amato L, Vecchi S, Davoli M, Kirchmayer U, et al. (2006) Oral naltrexone maintenance treatment for opioid dependence. Cochrane Database Syst Rev 1: CD001333.
18. Johansson BA, Berglund M, Lindgren A, (2006) Efficacy of maintenance treatment with naltrexone for opioid dependence: a meta-analytical review. Addiction 101: 491-503.
19. Krupitsky EM, Zvartau EE, Masalov DV, Tsoy MV, et al. (2006) Naltrexone with or without fluoxetine for preventing relapse to heroin addiction in St. Petersburg, Russia. J Subst Abuse Treat 31: 319-328.
20. Krupitsky EM, Zvartau EE, Masalov DV, Tsoi MV, Burakov AM, et al. (2004) Naltrexone for heroin dependence treatment in St. Petersburg, Russia. J Subst Abuse Treat 26: 285-294.
21. Johnson RE, Chutuape MA, Strain EC, Walsh SL, Stitzer ML, et al. (2000) A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. N Engl J Med 343: 1290-1297.
22. Mattick RP, Kimber J, Breen C, Davoli M, (2003) Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2: CD002207.
23. Stotts AL, Dodrill CL, Kosten TR, (2009) Opioid dependence treatment: options in pharmacotherapy. Expert Opin Pharmacother 10(11): 1727-1740.
24. Metzger DS, Zhang Y, (2010) Drug treatment as HIV prevention: expanding treatment options. Curr HIV/AIDS Rep 7(4): 220-225.
25. Metzger DS, Woody GE, O'Brien CP (2010) Drug treatment as HIV prevention: a research update. J Acquir Immune Defic Syndr (Suppl 1): S32-S36.
26. Milby JB, Schumacher JE, Wallace D, Vuchinich R, Mennemeyer ST, et al. (2010) Effects of sustained abstinence among treated substance-abusing homeless persons on housing and employment. Am J Public Health 100(5): 913-918.
27. Basu A, Paltiel AD, Pollack HA, (2008) Social costs of robbery and the cost-effectiveness of substance abuse treatment. Health Econ 17(8): 927-946.
28. Vucinovic M, Roje D, Vucinovic Z, Capkum V, Bucat M, et al. (2008) Maternal and neonatal effects of substance abuse during pregnancy: our ten-year experience. Yonsei Med J 49(5): 705-713.
29. Schaub M, Chtenguelov V, Subata E, Weiler G, Uchtenhagen A, (2010) Feasibility of buprenorphine and methadone maintenance programmes among users of home made opioids in Ukraine. Int J Drug Policy 21(3): 229-233.
30. Xie H, Drake RE, McHugo GJ, Xie L, Mohandas A, (2010) The 10-year course of remission, abstinence, and recovery in dual diagnosis. J Subst Abuse Treat 39(2): 132-140.
31. Reece AS, (2009) Comparative treatment and mortality correlates and adverse event profile of implant naltrexone and sublingual buprenorphine. J Subst Abuse Treat 37(3): 256-265.